Development continues on MS drug Nerventra® (laquinimod)

[MSUK]

Development continues on MS drug Nerventra® (laquinimod) following the EMA’s CHMP negative opinion

Teva Pharmaceutical Industries Ltd and Active Biotech announced today that both companies remain committed to the Nerventra® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)........... Read more - http://www.ms-uk.org/laquinimod